229 related articles for article (PubMed ID: 35938508)
21. Human CDK12 and CDK13, multi-tasking CTD kinases for the new millenium.
Greenleaf AL
Transcription; 2019 Apr; 10(2):91-110. PubMed ID: 30319007
[TBL] [Abstract][Full Text] [Related]
22. CDK12 Inhibition Reverses De Novo and Acquired PARP Inhibitor Resistance in BRCA Wild-Type and Mutated Models of Triple-Negative Breast Cancer.
Johnson SF; Cruz C; Greifenberg AK; Dust S; Stover DG; Chi D; Primack B; Cao S; Bernhardy AJ; Coulson R; Lazaro JB; Kochupurakkal B; Sun H; Unitt C; Moreau LA; Sarosiek KA; Scaltriti M; Juric D; Baselga J; Richardson AL; Rodig SJ; D'Andrea AD; Balmaña J; Johnson N; Geyer M; Serra V; Lim E; Shapiro GI
Cell Rep; 2016 Nov; 17(9):2367-2381. PubMed ID: 27880910
[TBL] [Abstract][Full Text] [Related]
23. Discovery of Potent and Selective CDK9 Degraders for Targeting Transcription Regulation in Triple-Negative Breast Cancer.
Wei D; Wang H; Zeng Q; Wang W; Hao B; Feng X; Wang P; Song N; Kan W; Huang G; Zhou X; Tan M; Zhou Y; Huang R; Li J; Chen XH
J Med Chem; 2021 Oct; 64(19):14822-14847. PubMed ID: 34538051
[TBL] [Abstract][Full Text] [Related]
24. Activity of BET-proteolysis targeting chimeric (PROTAC) compounds in triple negative breast cancer.
Noblejas-López MDM; Nieto-Jimenez C; Burgos M; Gómez-Juárez M; Montero JC; Esparís-Ogando A; Pandiella A; Galán-Moya EM; Ocaña A
J Exp Clin Cancer Res; 2019 Aug; 38(1):383. PubMed ID: 31470872
[TBL] [Abstract][Full Text] [Related]
25. Development of PROTAC degrader probe of CDK4/6 based on DCAF16.
Pu C; Liu Y; Deng R; Xu Q; Wang S; Zhang H; Luo D; Ma X; Tong Y; Li R
Bioorg Chem; 2023 Sep; 138():106637. PubMed ID: 37276679
[TBL] [Abstract][Full Text] [Related]
26. Design and characterization of PROTAC degraders specific to protein N-terminal methyltransferase 1.
Zhou Q; Wu W; Jia K; Qi G; Sun XS; Li P
Eur J Med Chem; 2022 Dec; 244():114830. PubMed ID: 36228414
[TBL] [Abstract][Full Text] [Related]
27. AR-A014418 regulates intronic polyadenylation and transcription of PD-L1 through inhibiting CDK12 and CDK13 in tumor cells.
Zhang G; Lan B; Zhang X; Lin M; Liu Y; Chen J; Guo F
J Immunother Cancer; 2023 May; 11(5):. PubMed ID: 37164450
[TBL] [Abstract][Full Text] [Related]
28. Cdk12 and Cdk13 regulate axonal elongation through a common signaling pathway that modulates Cdk5 expression.
Chen HR; Lin GT; Huang CK; Fann MJ
Exp Neurol; 2014 Nov; 261():10-21. PubMed ID: 24999027
[TBL] [Abstract][Full Text] [Related]
29. Discovery of Highly Potent Nicotinamide Phosphoribosyltransferase Degraders for Efficient Treatment of Ovarian Cancer.
Bi K; Cheng J; He S; Fang Y; Huang M; Sheng C; Dong G
J Med Chem; 2023 Jan; 66(1):1048-1062. PubMed ID: 36563407
[TBL] [Abstract][Full Text] [Related]
30. The Cyclin K/Cdk12 complex maintains genomic stability via regulation of expression of DNA damage response genes.
Blazek D; Kohoutek J; Bartholomeeusen K; Johansen E; Hulinkova P; Luo Z; Cimermancic P; Ule J; Peterlin BM
Genes Dev; 2011 Oct; 25(20):2158-72. PubMed ID: 22012619
[TBL] [Abstract][Full Text] [Related]
31. Targeting MYC dependency in ovarian cancer through inhibition of CDK7 and CDK12/13.
Zeng M; Kwiatkowski NP; Zhang T; Nabet B; Xu M; Liang Y; Quan C; Wang J; Hao M; Palakurthi S; Zhou S; Zeng Q; Kirschmeier PT; Meghani K; Leggett AL; Qi J; Shapiro GI; Liu JF; Matulonis UA; Lin CY; Konstantinopoulos PA; Gray NS
Elife; 2018 Nov; 7():. PubMed ID: 30422115
[TBL] [Abstract][Full Text] [Related]
32. Dual inhibition of CDK12 and CDK13 uncovers actionable vulnerabilities in patient-derived ovarian cancer organoids.
Cesari E; Ciucci A; Pieraccioli M; Caggiano C; Nero C; Bonvissuto D; Sillano F; Buttarelli M; Piermattei A; Loverro M; Camarda F; Greco V; De Bonis M; Minucci A; Gallo D; Urbani A; Vizzielli G; Scambia G; Sette C
J Exp Clin Cancer Res; 2023 May; 42(1):126. PubMed ID: 37202753
[TBL] [Abstract][Full Text] [Related]
33. Discovery of AXL Degraders with Improved Potencies in Triple-Negative Breast Cancer (TNBC) Cells.
He R; Song Z; Bai Y; He S; Huang J; Wang Y; Zhou F; Huang W; Guo J; Wang Z; Tu ZC; Ren X; Zhang Z; Xu J; Ding K
J Med Chem; 2023 Feb; 66(3):1873-1891. PubMed ID: 36695404
[TBL] [Abstract][Full Text] [Related]
34. The promise and current status of CDK12/13 inhibition for the treatment of cancer.
Tadesse S; Duckett DR; Monastyrskyi A
Future Med Chem; 2021 Jan; 13(2):117-141. PubMed ID: 33295810
[TBL] [Abstract][Full Text] [Related]
35. Discovery of Novel Polycyclic Heterocyclic Derivatives from Evodiamine for the Potential Treatment of Triple-Negative Breast Cancer.
Xu S; Yao H; Qiu Y; Zhou M; Li D; Wu L; Yang DH; Chen ZS; Xu J
J Med Chem; 2021 Dec; 64(23):17346-17365. PubMed ID: 34844412
[TBL] [Abstract][Full Text] [Related]
36. Discovery of ERD-308 as a Highly Potent Proteolysis Targeting Chimera (PROTAC) Degrader of Estrogen Receptor (ER).
Hu J; Hu B; Wang M; Xu F; Miao B; Yang CY; Wang M; Liu Z; Hayes DF; Chinnaswamy K; Delproposto J; Stuckey J; Wang S
J Med Chem; 2019 Feb; 62(3):1420-1442. PubMed ID: 30990042
[TBL] [Abstract][Full Text] [Related]
37. Structure-guided discovery of novel potent and efficacious proteolysis targeting chimera (PROTAC) degrader of BRD4.
Xiang W; Wang Q; Ran K; Ren J; Shi Y; Yu L
Bioorg Chem; 2021 Oct; 115():105238. PubMed ID: 34390970
[TBL] [Abstract][Full Text] [Related]
38. Discovery of SMD-3040 as a Potent and Selective SMARCA2 PROTAC Degrader with Strong
Yang L; Tu W; Huang L; Miao B; Kaneshige A; Jiang W; Leng L; Wang M; Wen B; Sun D; Wang S
J Med Chem; 2023 Aug; 66(15):10761-10781. PubMed ID: 37523716
[TBL] [Abstract][Full Text] [Related]
39. Induction of BRCAness in Triple-Negative Breast Cancer by a CDK12/13 Inhibitor Improves Chemotherapy.
Hopkins JL; Zou L
Cancer Cell; 2019 Nov; 36(5):461-463. PubMed ID: 31715127
[TBL] [Abstract][Full Text] [Related]
40. Synthesis and biological evaluation of a tumor-selective degrader of PARP1.
Pu C; Wang S; Luo D; Liu Y; Ma X; Zhang H; Yu S; Lan S; Huang Q; Deng R; He X; Li R
Bioorg Med Chem; 2022 Sep; 69():116908. PubMed ID: 35780655
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
